Concepedia

Author

Rosemarie de Haan

The Netherlands Cancer InstituteORCID

Also Known As

R. De Haan, R. de Haan, Rosemarie de Haan

35

Publications

319

Citations

7

H-Index

10

Concepts

All Affiliations

The Netherlands Cancer InstituteOncode InstituteUniversity of EdinburghUtrecht UniversityUniversity of Amsterdam
RD

About

Rosemarie de Haan is an author at The Netherlands Cancer Institute specializing in radiation oncology, tumor biology, and radiation therapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

111

2

Pharmacology

1

1

111

3

Radiation Therapy

1

1

111

4

Tumor Biology

1

1

111

5

Cancer Research

1

1

111

Rosemarie de Haan

×

7

Publications

311

Citations

7

H-Index

YearCitations

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells

Caroline V.M. Verhagen, Rosemarie de Haan, Floor Hageman,

Radiotherapy and Oncology

2015

111

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen,

Clinical Cancer Research

2020

54

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

Rosemarie de Haan, Erik van Werkhoven, Michel M. van den Heuvel,

BMC Cancer

2019

47

Retinal Arteriolar Geometry is Associated with Cerebral White Matter Hyperintensities on Magnetic Resonance Imaging

Fergus Doubal, Rosemarie de Haan, Petra E. Cohn‐Hokke,

International Journal of Stroke

2010

42

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials

Rosemarie de Haan, Dick Pluim, Baukelien van Triest,

Radiotherapy and Oncology

2017

23

Retinal arteriolar geometry is associated with cerebral white matter hyperintensities on MRI

Fergus Doubal, Rosemarie de Haan, Tom MacGillivray,

Edinburgh Research Archive (University of Edinburgh)

2010

17

Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples

Erik van Werkhoven, Samantha Hinsley, Eleni Frangou,

BMC Medical Research Methodology

2020

17

Page 1